HPV-Positive Head and Neck Cancer

MONDO:0044926 Pathograph 4 head and neck squamous cell carcinoma

HPV-positive head and neck squamous cell carcinoma (HNSCC) is a distinct clinical and molecular entity driven by high-risk human papillomavirus infection, primarily HPV-16. It predominantly affects the oropharynx (tonsils and base of tongue) and has increased dramatically in incidence over recent decades, particularly in younger patients. HPV-positive HNSCC has a markedly better prognosis than HPV-negative disease, with 5-year survival rates exceeding 80% in non-smoking patients. The oncogenic mechanisms parallel those of cervical cancer, with E6 and E7 oncoproteins inactivating p53 and pRB, respectively.

Ask OpenScientist

Ask a research question about HPV-Positive Head and Neck Cancer. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
0
Inheritance
4
Pathophysiology
1
Histopathology
6
Phenotypes
4
Pathograph
3
Genes
4
Treatments
2
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
10
References
1
Deep Research
🏷

Classifications

Harrison's Chapter
cancer solid tumor
ICD-O Morphology
Squamous Cell Carcinoma
◆

Subtypes

2
Tonsillar Squamous Cell Carcinoma
The most common site for HPV-positive oropharyngeal carcinoma, arising from the palatine tonsils within the specialized lymphoepithelium of the tonsillar crypts.
Base of Tongue Squamous Cell Carcinoma
HPV-positive carcinoma arising from the lingual tonsils at the base of the tongue, another major site of oropharyngeal involvement.
⚙

Pathophysiology

4
E6-Mediated p53 Degradation
HPV E6 oncoprotein recruits the E3 ubiquitin ligase E6AP to target p53 for proteasomal degradation, eliminating DNA damage checkpoints and allowing survival of cells with genomic instability. Unlike HPV-negative HNSCC, TP53 mutations are rare in HPV-positive tumors.
squamous epithelial cell link
proteasome-mediated ubiquitin-dependent protein catabolic process link ↑ INCREASED apoptotic process link ↓ DECREASED
oropharynx link
Downstream
Loss of DNA Damage Response p53 degradation abolishes G1/S and G2/M checkpoints
E7-Mediated pRB Inactivation
HPV E7 oncoprotein binds and degrades the retinoblastoma protein (pRB), releasing E2F transcription factors to drive S-phase entry. This causes compensatory overexpression of p16INK4a, which serves as a clinical biomarker for HPV-associated tumors.
G1/S transition of mitotic cell cycle link ⚠ ABNORMAL cell cycle checkpoint signaling link ↓ DECREASED
Downstream
Uncontrolled Cell Proliferation E2F release activates genes required for DNA replication
Viral Oncogene Integration
HPV genome integration into the host chromosome disrupts the E2 viral repressor, leading to constitutive E6/E7 expression. However, episomal HPV may also drive carcinogenesis in some HPV-positive oropharyngeal cancers.
viral DNA integration into host DNA link
Immune Evasion
HPV-positive HNSCC evades immune surveillance through downregulation of antigen presentation and PD-L1 expression. However, these tumors are generally more immunogenic than HPV-negative HNSCC, contributing to better prognosis and response to immunotherapy.
negative regulation of T cell mediated immunity link ↑ INCREASED
✶

Histopathology

1
Squamous Cell Carcinoma VERY_FREQUENT
Head and neck squamous cell carcinoma is a squamous carcinoma of the head and neck.
Show evidence (1 reference)
PMID:36414699 SUPPORT
"Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer"
Abstract explicitly names head and neck squamous cell carcinoma.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Referential integrity issues (2):
  • Target 'Loss of DNA Damage Response' (from 'E6-Mediated p53 Degradation') not found in named elements
  • Target 'Uncontrolled Cell Proliferation' (from 'E7-Mediated pRB Inactivation') not found in named elements
Pathograph: causal mechanism network for HPV-Positive Head and Neck Cancer Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Cardiovascular 1
Neck Mass FREQUENT Lymphadenopathy (HP:0002716)
Show evidence (1 reference)
PMID:24652023 SUPPORT Human Clinical
"Patients who were HPV-positive were more likely to initially notice a neck mass than HPV-negative patients (51% vs 18%; P = .02)"
Retrospective single-institution review of oropharyngeal squamous cell carcinoma patients found neck mass to be the most common initial symptom in HPV-positive disease (51%), supporting its classification as a frequent and diagnostic phenotype.
Digestive 2
Dysphagia OCCASIONAL Dysphagia (HP:0002015)
Show evidence (1 reference)
PMID:24652023 PARTIAL Human Clinical
"Patients who were HPV-positive more commonly complained of a neck mass as the initial symptom, whereas HPV-negative patients more commonly had symptoms related to the primary tumor site, including sore throat, dysphagia, and/or odynophagia."
Same OPSCC cohort reports dysphagia as an initial symptom in 10% of HPV-positive patients (compared with 41% of HPV-negative). Dysphagia is less common at presentation in HPV-positive disease but develops as tumors progress, supporting its inclusion as a frequent phenotype during disease course.
Odynophagia OCCASIONAL Odynophagia (HP:0032043)
Show evidence (1 reference)
PMID:24652023 PARTIAL Human Clinical
"Patients who were HPV-positive more commonly complained of a neck mass as the initial symptom, whereas HPV-negative patients more commonly had symptoms related to the primary tumor site, including sore throat, dysphagia, and/or odynophagia."
Same OPSCC cohort identifies odynophagia as an initial symptom in 6% of HPV-positive patients (compared with 24% in HPV-negative). Less common at initial presentation in HPV-positive disease but occurs with larger or ulcerative primary tumors as the disease progresses.
Respiratory 1
Sore Throat OCCASIONAL Pharyngitis (HP:0025439)
Show evidence (1 reference)
PMID:24652023 PARTIAL Human Clinical
"Patients who were HPV-positive more commonly complained of a neck mass as the initial symptom, whereas HPV-negative patients more commonly had symptoms related to the primary tumor site, including sore throat, dysphagia, and/or odynophagia."
Same OPSCC cohort lists sore throat among the recognized initial symptoms in oropharyngeal cancer, with the study reporting sore throat in 28% of HPV-positive and 53% of HPV-negative patients, supporting its classification as an occasional presenting symptom.
Voice 1
Hoarseness OCCASIONAL Hoarse voice (HP:0001609)
Show evidence (1 reference)
PMID:6954395 SUPPORT Human Clinical
"The presenting features of 522 cases are summarised. They emphasize that the following clinical features are significant, especially in a patient who smokes or drinks: local pain, pain referred to the ear, hoarseness, dysphagia, dyspnoea and stridor, persistent sore throat, nasal obstruction,..."
Retrospective review of 522 head and neck cancer cases lists hoarseness among the recognized significant clinical presenting features, supporting its inclusion as an occasional phenotype that may indicate large tumors or laryngeal involvement.
Growth 1
Weight Loss OCCASIONAL Weight loss (HP:0001824)
Show evidence (1 reference)
PMID:17277925 SUPPORT Human Clinical
"Critical weight loss was present in 19% of the patients. Patients with cancer in the hypopharynx, oropharynx/oral cavity and supraglottic larynx had the highest risk for critical weight loss."
Cohort study of 407 head and neck cancer patients at diagnosis found critical weight loss (>=5% in 1 month or >=10% in 6 months) in 19% of patients before treatment, with oropharyngeal cancer patients at highest risk. Supports weight loss as an occasional pre-treatment phenotype in HPV-positive oropharyngeal cancer.
🧬

Genetic Associations

3
TP53 (Wild-type (rarely mutated))
PIK3CA (Somatic Mutations)
CDKN2A (Rarely Inactivated)
💊

Treatments

4
Definitive Chemoradiation
Action: radiation therapy MAXO:0000014
Agent: cisplatin ↗
Concurrent cisplatin-based chemotherapy with intensity-modulated radiation therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal cancers. The excellent prognosis has led to de-escalation trials aiming to reduce long-term treatment toxicity.
Transoral Robotic Surgery
Action: surgical procedure MAXO:0000004
Minimally invasive transoral robotic surgery (TORS) allows resection of oropharyngeal tumors with reduced morbidity compared to traditional open surgery. May be followed by adjuvant radiation based on pathologic features.
Immunotherapy
Action: immunotherapy Ontology label: Immunotherapy NCIT:C15262
PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or metastatic HNSCC. HPV-positive tumors may have enhanced immunogenicity due to viral antigen expression, though clinical response rates are similar to HPV-negative disease.
HPV Vaccination
Action: vaccination MAXO:0001017
Prophylactic HPV vaccination is expected to reduce the incidence of HPV-positive oropharyngeal cancer, though the impact will not be fully realized for several decades due to the long latency between infection and cancer development.
🔬

Biochemical Markers

2
p16 Immunohistochemistry
HPV DNA/RNA Testing
{ }

Source YAML

click to show 
name: HPV-Positive Head and Neck Cancer
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-04-11T21:17:25Z'
description: >-
  HPV-positive head and neck squamous cell carcinoma (HNSCC) is a distinct clinical
  and molecular entity driven by high-risk human papillomavirus infection, primarily
  HPV-16. It predominantly affects the oropharynx (tonsils and base of tongue) and
  has increased dramatically in incidence over recent decades, particularly in younger
  patients. HPV-positive HNSCC has a markedly better prognosis than HPV-negative
  disease, with 5-year survival rates exceeding 80% in non-smoking patients. The
  oncogenic mechanisms parallel those of cervical cancer, with E6 and E7 oncoproteins
  inactivating p53 and pRB, respectively.
categories:
- Head and Neck Cancer
- Viral-Associated Cancer
- HPV-Related Cancer
- Oropharyngeal Cancer
parents:
- head and neck squamous cell carcinoma
has_subtypes:
- name: Tonsillar Squamous Cell Carcinoma
  description: >-
    The most common site for HPV-positive oropharyngeal carcinoma, arising from
    the palatine tonsils within the specialized lymphoepithelium of the tonsillar
    crypts.
- name: Base of Tongue Squamous Cell Carcinoma
  description: >-
    HPV-positive carcinoma arising from the lingual tonsils at the base of the
    tongue, another major site of oropharyngeal involvement.
infectious_agent:
- name: Human Papillomavirus Type 16
  description: >-
    HPV-16 causes approximately 90% of HPV-positive oropharyngeal cancers. Unlike
    cervical cancer, HPV-18 plays a minor role in oropharyngeal carcinogenesis.
    Infection is believed to occur through orogenital contact.
  evidence:
  - reference: PMID:37861207
    reference_title: "Human papillomavirus and p16(INK4a) in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis."
    supports: SUPPORT
    snippet: "HPV16 accounts for the majority of HPV positive oropharyngeal SCC cases."
    explanation: "Supports HPV16 predominance in HPV-positive oropharyngeal cancers."
  infectious_agent_term:
    preferred_term: Human papillomavirus 16
    term:
      id: NCBITaxon:333760
      label: Human papillomavirus 16
pathophysiology:
- name: E6-Mediated p53 Degradation
  description: >-
    HPV E6 oncoprotein recruits the E3 ubiquitin ligase E6AP to target p53 for
    proteasomal degradation, eliminating DNA damage checkpoints and allowing
    survival of cells with genomic instability. Unlike HPV-negative HNSCC,
    TP53 mutations are rare in HPV-positive tumors.
  cell_types:
  - preferred_term: squamous epithelial cell
    term:
      id: CL:0000076
      label: squamous epithelial cell
  biological_processes:
  - preferred_term: proteasome-mediated ubiquitin-dependent protein catabolic process
    modifier: INCREASED
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
  locations:
  - preferred_term: oropharynx
    term:
      id: UBERON:0001729
      label: oropharynx
  downstream:
  - target: Loss of DNA Damage Response
    description: p53 degradation abolishes G1/S and G2/M checkpoints
- name: E7-Mediated pRB Inactivation
  description: >-
    HPV E7 oncoprotein binds and degrades the retinoblastoma protein (pRB),
    releasing E2F transcription factors to drive S-phase entry. This causes
    compensatory overexpression of p16INK4a, which serves as a clinical
    biomarker for HPV-associated tumors.
  biological_processes:
  - preferred_term: G1/S transition of mitotic cell cycle
    modifier: ABNORMAL
    term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
  - preferred_term: cell cycle checkpoint signaling
    modifier: DECREASED
    term:
      id: GO:0000075
      label: cell cycle checkpoint signaling
  downstream:
  - target: Uncontrolled Cell Proliferation
    description: E2F release activates genes required for DNA replication
- name: Viral Oncogene Integration
  description: >-
    HPV genome integration into the host chromosome disrupts the E2 viral
    repressor, leading to constitutive E6/E7 expression. However, episomal
    HPV may also drive carcinogenesis in some HPV-positive oropharyngeal cancers.
  biological_processes:
  - preferred_term: viral DNA integration into host DNA
    term:
      id: GO:0044826
      label: viral genome integration into host DNA
- name: Immune Evasion
  description: >-
    HPV-positive HNSCC evades immune surveillance through downregulation of
    antigen presentation and PD-L1 expression. However, these tumors are
    generally more immunogenic than HPV-negative HNSCC, contributing to
    better prognosis and response to immunotherapy.
  biological_processes:
  - preferred_term: negative regulation of T cell mediated immunity
    modifier: INCREASED
    term:
      id: GO:0002710
      label: negative regulation of T cell mediated immunity
histopathology:
- name: Squamous Cell Carcinoma
  finding_term:
    preferred_term: Squamous Cell Carcinoma
    term:
      id: NCIT:C2929
      label: Squamous Cell Carcinoma
  frequency: VERY_FREQUENT
  description: Head and neck squamous cell carcinoma is a squamous carcinoma of the head and neck.
  evidence:
  - reference: PMID:36414699
    reference_title: "[The tumor microenvironment-relay station for prognosis and therapy response]."
    supports: SUPPORT
    snippet: "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer"
    explanation: Abstract explicitly names head and neck squamous cell carcinoma.

phenotypes:
- category: Head and Neck
  name: Neck Mass
  frequency: FREQUENT
  diagnostic: true
  description: >-
    Painless cervical lymphadenopathy is often the presenting symptom, frequently
    as a unilateral neck mass. The primary tumor may be small or occult while
    metastatic nodes are prominent.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  evidence:
  - reference: PMID:24652023
    reference_title: "Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients who were HPV-positive were more likely to initially notice a neck mass than HPV-negative patients (51% vs 18%; P = .02)"
    explanation: >-
      Retrospective single-institution review of oropharyngeal squamous
      cell carcinoma patients found neck mass to be the most common
      initial symptom in HPV-positive disease (51%), supporting its
      classification as a frequent and diagnostic phenotype.
- category: Head and Neck
  name: Dysphagia
  frequency: OCCASIONAL
  description: >-
    Difficulty swallowing develops as tumors grow in the tonsil or base of tongue,
    affecting the swallowing mechanism.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:24652023
    reference_title: "Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients who were HPV-positive more commonly complained of a neck mass as the initial symptom, whereas HPV-negative patients more commonly had symptoms related to the primary tumor site, including sore throat, dysphagia, and/or odynophagia."
    explanation: >-
      Same OPSCC cohort reports dysphagia as an initial symptom in 10%
      of HPV-positive patients (compared with 41% of HPV-negative).
      Dysphagia is less common at presentation in HPV-positive disease
      but develops as tumors progress, supporting its inclusion as a
      frequent phenotype during disease course.
- category: Head and Neck
  name: Odynophagia
  frequency: OCCASIONAL
  description: >-
    Painful swallowing may occur, particularly with larger primary tumors
    or ulcerative lesions.
  phenotype_term:
    preferred_term: Odynophagia
    term:
      id: HP:0032043
      label: Odynophagia
  evidence:
  - reference: PMID:24652023
    reference_title: "Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients who were HPV-positive more commonly complained of a neck mass as the initial symptom, whereas HPV-negative patients more commonly had symptoms related to the primary tumor site, including sore throat, dysphagia, and/or odynophagia."
    explanation: >-
      Same OPSCC cohort identifies odynophagia as an initial symptom
      in 6% of HPV-positive patients (compared with 24% in HPV-negative).
      Less common at initial presentation in HPV-positive disease but
      occurs with larger or ulcerative primary tumors as the disease
      progresses.
- category: Head and Neck
  name: Sore Throat
  frequency: OCCASIONAL
  description: >-
    Persistent unilateral sore throat or foreign body sensation may be an early
    symptom of tonsillar carcinoma.
  phenotype_term:
    preferred_term: Sore throat
    term:
      id: HP:0025439
      label: Pharyngitis
  evidence:
  - reference: PMID:24652023
    reference_title: "Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients who were HPV-positive more commonly complained of a neck mass as the initial symptom, whereas HPV-negative patients more commonly had symptoms related to the primary tumor site, including sore throat, dysphagia, and/or odynophagia."
    explanation: >-
      Same OPSCC cohort lists sore throat among the recognized initial
      symptoms in oropharyngeal cancer, with the study reporting sore
      throat in 28% of HPV-positive and 53% of HPV-negative patients,
      supporting its classification as an occasional presenting symptom.
- category: Head and Neck
  name: Hoarseness
  frequency: OCCASIONAL
  description: >-
    Voice changes may occur with large tumors or those involving the larynx
    or recurrent laryngeal nerve.
  phenotype_term:
    preferred_term: Hoarse voice
    term:
      id: HP:0001609
      label: Hoarse voice
  evidence:
  - reference: PMID:6954395
    reference_title: "The presenting symptoms of head and neck cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presenting features of 522 cases are summarised. They emphasize that the following clinical features are significant, especially in a patient who smokes or drinks: local pain, pain referred to the ear, hoarseness, dysphagia, dyspnoea and stridor, persistent sore throat, nasal obstruction, bleeding, problems fitting dentures and a neck lump."
    explanation: >-
      Retrospective review of 522 head and neck cancer cases lists
      hoarseness among the recognized significant clinical presenting
      features, supporting its inclusion as an occasional phenotype
      that may indicate large tumors or laryngeal involvement.
- category: Constitutional
  name: Weight Loss
  frequency: OCCASIONAL
  description: >-
    Unintentional weight loss may occur due to dysphagia or advanced disease,
    though patients often present with earlier-stage disease.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: PMID:17277925
    reference_title: "Critical weight loss in head and neck cancer--prevalence and risk factors at diagnosis: an explorative study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Critical weight loss was present in 19% of the patients. Patients with cancer in the hypopharynx, oropharynx/oral cavity and supraglottic larynx had the highest risk for critical weight loss."
    explanation: >-
      Cohort study of 407 head and neck cancer patients at diagnosis
      found critical weight loss (>=5% in 1 month or >=10% in 6 months)
      in 19% of patients before treatment, with oropharyngeal cancer
      patients at highest risk. Supports weight loss as an occasional
      pre-treatment phenotype in HPV-positive oropharyngeal cancer.
biochemical:
- name: p16 Immunohistochemistry
  notes: >-
    Strong, diffuse nuclear and cytoplasmic p16 staining serves as a surrogate
    marker for transcriptionally active HPV infection. The p16 positivity is
    due to pRB inactivation by E7, which removes feedback inhibition of CDKN2A
    expression. p16 IHC is used clinically for staging and prognostication.
- name: HPV DNA/RNA Testing
  notes: >-
    Detection of high-risk HPV DNA or E6/E7 mRNA confirms HPV-driven
    carcinogenesis. RNA detection is more specific for transcriptionally
    active infection than DNA detection alone.
genetic:
- name: TP53
  association: Wild-type (rarely mutated)
  notes: >-
    Unlike HPV-negative HNSCC where TP53 mutations occur in greater than 80% of
    cases, HPV-positive tumors typically have wild-type TP53 because p53 function
    is eliminated through E6-mediated degradation.
- name: PIK3CA
  association: Somatic Mutations
  notes: >-
    PIK3CA mutations occur in approximately 20-30% of HPV-positive HNSCC,
    activating PI3K/AKT/mTOR signaling. This is the most commonly mutated
    oncogene in HPV-positive tumors.
- name: CDKN2A
  association: Rarely Inactivated
  notes: >-
    CDKN2A (p16) is typically wild-type and overexpressed in HPV-positive HNSCC
    due to E7-mediated pRB inactivation, in contrast to HPV-negative HNSCC where
    CDKN2A is frequently deleted or silenced.
treatments:
- name: Definitive Chemoradiation
  description: >-
    Concurrent cisplatin-based chemotherapy with intensity-modulated radiation
    therapy (IMRT) is standard treatment for most HPV-positive oropharyngeal
    cancers. The excellent prognosis has led to de-escalation trials aiming
    to reduce long-term treatment toxicity.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
    therapeutic_agent:
    - preferred_term: cisplatin
      term:
        id: CHEBI:27899
        label: cisplatin
- name: Transoral Robotic Surgery
  description: >-
    Minimally invasive transoral robotic surgery (TORS) allows resection of
    oropharyngeal tumors with reduced morbidity compared to traditional open
    surgery. May be followed by adjuvant radiation based on pathologic features.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Immunotherapy
  description: >-
    PD-1 inhibitors (pembrolizumab, nivolumab) are approved for recurrent or
    metastatic HNSCC. HPV-positive tumors may have enhanced immunogenicity
    due to viral antigen expression, though clinical response rates are similar
    to HPV-negative disease.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
- name: HPV Vaccination
  description: >-
    Prophylactic HPV vaccination is expected to reduce the incidence of
    HPV-positive oropharyngeal cancer, though the impact will not be fully
    realized for several decades due to the long latency between infection
    and cancer development.
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
disease_term:
  preferred_term: oropharyngeal carcinoma
  term:
    id: MONDO:0044926
    label: oropharyngeal carcinoma

classifications:
  icdo_morphology:
    classification_value: Squamous Cell Carcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
references:
- reference: DOI:10.1001/jamanetworkopen.2024.31807
  title: Human Papillomavirus Vaccination and Human Papillomavirus–Related Cancer Rates
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: Human Papillomavirus Vaccination and Human Papillomavirus–Related Cancer Rates
    supporting_text: ImportanceTo inform the design and implementation of targeted interventions to reduce the future burden of human papillomavirus (HPV)–related cancers in Texas, it is necessary to examine the county and health service region (HSR) levels of (1) the proportion of children and teenagers aged 9 to 17 years who initiated and were up to date for HPV vaccination series and (2) HPV-related cancer incidence rates (IRs).ObjectiveTo evaluate temporal trends and geospatial patterns of HPV vaccination initiation and up-to-date status as well as HPV-related cancer rates at county and HSR levels in Texas.Design, Setting, and ParticipantsThis population-based cross-sectional study used data from the Texas Immunization Registry, the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program database, and Texas Department of State Health Services annual population counts from 2006 to 2022.
    evidence:
    - reference: DOI:10.1001/jamanetworkopen.2024.31807
      reference_title: Human Papillomavirus Vaccination and Human Papillomavirus–Related Cancer Rates
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: ImportanceTo inform the design and implementation of targeted interventions to reduce the future burden of human papillomavirus (HPV)–related cancers in Texas, it is necessary to examine the county and health service region (HSR) levels of (1) the proportion of children and teenagers aged 9 to 17 years who initiated and were up to date for HPV vaccination series and (2) HPV-related cancer incidence rates (IRs).ObjectiveTo evaluate temporal trends and geospatial patterns of HPV vaccination initiation and up-to-date status as well as HPV-related cancer rates at county and HSR levels in Texas.Design, Setting, and ParticipantsThis population-based cross-sectional study used data from the Texas Immunization Registry, the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program database, and Texas Department of State Health Services annual population counts from 2006 to 2022.
      explanation: Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
- reference: DOI:10.1007/s00262-024-03789-0
  title: 'Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13+ CD4+ T cell activation in oropharyngeal cancer: implications for immunotherapy'
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: Human papillomavirus (HPV) infection has become an important etiological driver of oropharyngeal squamous cell carcinoma (OPSCC), leading to unique tumor characteristics.
    supporting_text: Human papillomavirus (HPV) infection has become an important etiological driver of oropharyngeal squamous cell carcinoma (OPSCC), leading to unique tumor characteristics.
    evidence:
    - reference: DOI:10.1007/s00262-024-03789-0
      reference_title: 'Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13+ CD4+ T cell activation in oropharyngeal cancer: implications for immunotherapy'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Human papillomavirus (HPV) infection has become an important etiological driver of oropharyngeal squamous cell carcinoma (OPSCC), leading to unique tumor characteristics.
      explanation: Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
- reference: DOI:10.1007/s11845-024-03715-4
  title: 'HPV overtakes smoking as the leading cause of oropharyngeal cancer in Ireland: experience of a head and neck surgery tertiary referral centre'
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: Worldwide, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) caused by human papillomavirus (HPV), a sexually transmitted virus, is increasing.
    supporting_text: Worldwide, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) caused by human papillomavirus (HPV), a sexually transmitted virus, is increasing.
    evidence:
    - reference: DOI:10.1007/s11845-024-03715-4
      reference_title: 'HPV overtakes smoking as the leading cause of oropharyngeal cancer in Ireland: experience of a head and neck surgery tertiary referral centre'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Worldwide, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) caused by human papillomavirus (HPV), a sexually transmitted virus, is increasing.
      explanation: Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
- reference: DOI:10.1038/s41416-019-0414-9
  title: 'Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach'
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: 'Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach'
    supporting_text: 'Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach'
- reference: DOI:10.1038/s41416-024-02655-1
  title: 'Navigating therapeutic strategies: HPV classification in head and neck cancer'
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: The World Health Organisation recognised human papillomavirus (HPV) as the cause of multiple cancers, including head and neck cancers.
    supporting_text: The World Health Organisation recognised human papillomavirus (HPV) as the cause of multiple cancers, including head and neck cancers.
    evidence:
    - reference: DOI:10.1038/s41416-024-02655-1
      reference_title: 'Navigating therapeutic strategies: HPV classification in head and neck cancer'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The World Health Organisation recognised human papillomavirus (HPV) as the cause of multiple cancers, including head and neck cancers.
      explanation: Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
- reference: DOI:10.1159/000527951
  title: Aptima HR-HPV Testing of Cytology Specimens Is an Effective Supplement for p16 Staining to Improve Diagnostic Accuracy for HPV-Related Oropharyngeal Squamous Cell Carcinoma
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: Aptima HR-HPV Testing of Cytology Specimens Is an Effective Supplement for p16 Staining to Improve Diagnostic Accuracy for HPV-Related Oropharyngeal Squamous Cell Carcinoma
    supporting_text: Regarding a small proportion of oropharyngeal squamous cell carcinoma (OPSCC) patients who tested p16-positive but human papillomavirus (HPV)-negative, we attempted to perform HPV testing to improve the accuracy of HPV detection in OPSCC patients.
    evidence:
    - reference: DOI:10.1159/000527951
      reference_title: Aptima HR-HPV Testing of Cytology Specimens Is an Effective Supplement for p16 Staining to Improve Diagnostic Accuracy for HPV-Related Oropharyngeal Squamous Cell Carcinoma
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Regarding a small proportion of oropharyngeal squamous cell carcinoma (OPSCC) patients who tested p16-positive but human papillomavirus (HPV)-negative, we attempted to perform HPV testing to improve the accuracy of HPV detection in OPSCC patients.
      explanation: Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
- reference: DOI:10.1186/s13027-024-00592-5
  title: A SEER-based analysis of trends in HPV-associated oropharyngeal squamous cell carcinoma
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: The proportional trends of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) according to various factors have not been analyzed in detail in previous studies.
    supporting_text: The proportional trends of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) according to various factors have not been analyzed in detail in previous studies.
    evidence:
    - reference: DOI:10.1186/s13027-024-00592-5
      reference_title: A SEER-based analysis of trends in HPV-associated oropharyngeal squamous cell carcinoma
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The proportional trends of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) according to various factors have not been analyzed in detail in previous studies.
      explanation: Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
- reference: DOI:10.3390/biom14080925
  title: 'The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer'
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal squamous cell carcinoma (OPSCC), is an increasingly prevalent pathology worldwide, especially in developed countries.
    supporting_text: Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal squamous cell carcinoma (OPSCC), is an increasingly prevalent pathology worldwide, especially in developed countries.
    evidence:
    - reference: DOI:10.3390/biom14080925
      reference_title: 'The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal squamous cell carcinoma (OPSCC), is an increasingly prevalent pathology worldwide, especially in developed countries.
      explanation: Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
- reference: DOI:10.3390/cancers15164080
  title: 'Human Papillomavirus-Associated Oropharyngeal Cancer: Global Epidemiology and Public Policy Implications'
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms.
    supporting_text: Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms.
    evidence:
    - reference: DOI:10.3390/cancers15164080
      reference_title: 'Human Papillomavirus-Associated Oropharyngeal Cancer: Global Epidemiology and Public Policy Implications'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms.
      explanation: Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
- reference: DOI:10.3390/cancers16152733
  title: 'De-Escalation Strategies in HPV-Associated Oropharynx Cancer: A Historical Perspective with Future Direction'
  found_in:
  - HPV_Positive_Head_and_Neck_Cancer-deep-research-falcon.md
  findings:
  - statement: The incidence of HPV-related oropharyngeal cancers has increased in recent decades.
    supporting_text: The incidence of HPV-related oropharyngeal cancers has increased in recent decades.
    evidence:
    - reference: DOI:10.3390/cancers16152733
      reference_title: 'De-Escalation Strategies in HPV-Associated Oropharynx Cancer: A Historical Perspective with Future Direction'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The incidence of HPV-related oropharyngeal cancers has increased in recent decades.
      explanation: Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
📚

References & Deep Research

References

10
DOI:10.1001/jamanetworkopen.2024.31807
Human Papillomavirus Vaccination and Human Papillomavirus–Related Cancer Rates
1 finding
Human Papillomavirus Vaccination and Human Papillomavirus–Related Cancer Rates
"ImportanceTo inform the design and implementation of targeted interventions to reduce the future burden of human papillomavirus (HPV)–related cancers in Texas, it is necessary to examine the county and health service region (HSR) levels of (1) the proportion of children and teenagers aged 9 to..."
Show evidence (1 reference)
DOI:10.1001/jamanetworkopen.2024.31807 SUPPORT Human Clinical
"ImportanceTo inform the design and implementation of targeted interventions to reduce the future burden of human papillomavirus (HPV)–related cancers in Texas, it is necessary to examine the county and health service region (HSR) levels of (1) the proportion of children and teenagers aged 9 to..."
Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
DOI:10.1007/s00262-024-03789-0
Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13+ CD4+ T cell activation in oropharyngeal cancer: implications for immunotherapy
1 finding
Human papillomavirus (HPV) infection has become an important etiological driver of oropharyngeal squamous cell carcinoma (OPSCC), leading to unique tumor characteristics.
"Human papillomavirus (HPV) infection has become an important etiological driver of oropharyngeal squamous cell carcinoma (OPSCC), leading to unique tumor characteristics."
Show evidence (1 reference)
DOI:10.1007/s00262-024-03789-0 SUPPORT Human Clinical
"Human papillomavirus (HPV) infection has become an important etiological driver of oropharyngeal squamous cell carcinoma (OPSCC), leading to unique tumor characteristics."
Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
DOI:10.1007/s11845-024-03715-4
HPV overtakes smoking as the leading cause of oropharyngeal cancer in Ireland: experience of a head and neck surgery tertiary referral centre
1 finding
Worldwide, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) caused by human papillomavirus (HPV), a sexually transmitted virus, is increasing.
"Worldwide, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) caused by human papillomavirus (HPV), a sexually transmitted virus, is increasing."
Show evidence (1 reference)
DOI:10.1007/s11845-024-03715-4 SUPPORT Human Clinical
"Worldwide, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) caused by human papillomavirus (HPV), a sexually transmitted virus, is increasing."
Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
DOI:10.1038/s41416-019-0414-9
Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach
1 finding
Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach
"Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach"
DOI:10.1038/s41416-024-02655-1
Navigating therapeutic strategies: HPV classification in head and neck cancer
1 finding
The World Health Organisation recognised human papillomavirus (HPV) as the cause of multiple cancers, including head and neck cancers.
"The World Health Organisation recognised human papillomavirus (HPV) as the cause of multiple cancers, including head and neck cancers."
Show evidence (1 reference)
DOI:10.1038/s41416-024-02655-1 SUPPORT Human Clinical
"The World Health Organisation recognised human papillomavirus (HPV) as the cause of multiple cancers, including head and neck cancers."
Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
DOI:10.1159/000527951
Aptima HR-HPV Testing of Cytology Specimens Is an Effective Supplement for p16 Staining to Improve Diagnostic Accuracy for HPV-Related Oropharyngeal Squamous Cell Carcinoma
1 finding
Aptima HR-HPV Testing of Cytology Specimens Is an Effective Supplement for p16 Staining to Improve Diagnostic Accuracy for HPV-Related Oropharyngeal Squamous Cell Carcinoma
"Regarding a small proportion of oropharyngeal squamous cell carcinoma (OPSCC) patients who tested p16-positive but human papillomavirus (HPV)-negative, we attempted to perform HPV testing to improve the accuracy of HPV detection in OPSCC patients."
Show evidence (1 reference)
DOI:10.1159/000527951 SUPPORT Human Clinical
"Regarding a small proportion of oropharyngeal squamous cell carcinoma (OPSCC) patients who tested p16-positive but human papillomavirus (HPV)-negative, we attempted to perform HPV testing to improve the accuracy of HPV detection in OPSCC patients."
Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
DOI:10.1186/s13027-024-00592-5
A SEER-based analysis of trends in HPV-associated oropharyngeal squamous cell carcinoma
1 finding
The proportional trends of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) according to various factors have not been analyzed in detail in previous studies.
"The proportional trends of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) according to various factors have not been analyzed in detail in previous studies."
Show evidence (1 reference)
DOI:10.1186/s13027-024-00592-5 SUPPORT Human Clinical
"The proportional trends of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) according to various factors have not been analyzed in detail in previous studies."
Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
DOI:10.3390/biom14080925
The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer
1 finding
Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal squamous cell carcinoma (OPSCC), is an increasingly prevalent pathology worldwide, especially in developed countries.
"Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal squamous cell carcinoma (OPSCC), is an increasingly prevalent pathology worldwide, especially in developed countries."
Show evidence (1 reference)
DOI:10.3390/biom14080925 SUPPORT Human Clinical
"Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal squamous cell carcinoma (OPSCC), is an increasingly prevalent pathology worldwide, especially in developed countries."
Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
DOI:10.3390/cancers15164080
Human Papillomavirus-Associated Oropharyngeal Cancer: Global Epidemiology and Public Policy Implications
1 finding
Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms.
"Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms."
Show evidence (1 reference)
DOI:10.3390/cancers15164080 SUPPORT Human Clinical
"Global trends in human papillomavirus (HPV)-associated head and neck cancers (HNC), specifically in the oropharynx subsite, have been dynamically changing, leading to new staging and treatment paradigms."
Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.
DOI:10.3390/cancers16152733
De-Escalation Strategies in HPV-Associated Oropharynx Cancer: A Historical Perspective with Future Direction
1 finding
The incidence of HPV-related oropharyngeal cancers has increased in recent decades.
"The incidence of HPV-related oropharyngeal cancers has increased in recent decades."
Show evidence (1 reference)
DOI:10.3390/cancers16152733 SUPPORT Other
"The incidence of HPV-related oropharyngeal cancers has increased in recent decades."
Deep research cited this publication as relevant literature for HPV Positive Head and Neck Cancer.

Deep Research

1
Falcon ▸
HPV-Positive Head and Neck Cancer (HPV+ HNSCC) — Disease Characteristics Research Report
Edison Scientific Literature 33 citations 2026-04-05T16:41:40.966188

HPV-Positive Head and Neck Cancer (HPV+ HNSCC) — Disease Characteristics Research Report

Target Disease

  • Disease Name: HPV-Positive Head and Neck Cancer (HPV+ HNSCC), with emphasis on HPV-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC), the dominant clinical entity in most datasets.
  • MONDO ID: Not retrieved in the available evidence corpus.
  • Category: Virus-associated squamous cell carcinoma (upper aerodigestive tract), primarily oropharynx.

1. Disease Information

Overview (current understanding)

HPV-positive head and neck squamous cell carcinoma is a subset of HNSCC in which oncogenic high-risk HPV infection is an etiologic driver; clinically this is most strongly associated with oropharyngeal squamous cell carcinoma (tonsil and base of tongue). Single-cell and translational studies treat HPV+ OPSCC as a distinct disease entity with unique immune and molecular features and generally more favorable outcomes compared with HPV-negative OPSCC. (yan2024decipheringtheinterplay pages 1-2, ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3)

Abstract-quotable definition/epidemiology framing: - Yan et al. (2024) open with: “Human papillomavirus (HPV) infection has become an important etiological driver of oropharyngeal squamous cell carcinoma (OPSCC), leading to unique tumor characteristics.” (Published online 6 Aug 2024; https://doi.org/10.1007/s00262-024-03789-0) (yan2024decipheringtheinterplay pages 1-2)

Synonyms / alternative names

  • HPV-associated head and neck squamous cell carcinoma
  • HPV-mediated oropharyngeal squamous cell carcinoma
  • HPV-positive oropharyngeal cancer / HPV-associated OPSCC

Key identifiers (ontologies)

The provided evidence did not include explicit ontology identifiers (ICD-10/ICD-11, MeSH, MONDO). Consequently, this section is incomplete for identifiers. The staging context emphasizes AJCC/UICC TNM 8th edition separation/stratification of HPV-associated OPSCC (via p16 surrogate testing), but the manual itself was not retrieved in full as a citable source in this run. (Craig et al. discuss TNM8 implications) (craig2019recommendationsfordetermining pages 1-2)

Evidence provenance

Evidence here is derived primarily from: - Aggregated resources (registry/SEER/NCDB-like cohorts and reviews) (kim2024aseerbasedanalysis pages 1-2, ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3) - Single-center retrospective cohorts (cleere2024hpvovertakessmoking pages 1-2) - Clinical trial registry entries (ClinicalTrials.gov) (NCT01898494 chunk 1, NCT02215265 chunk 1) - Molecular/translational datasets (single-cell RNA-seq) (yan2024decipheringtheinterplay pages 1-2)

2. Etiology

Disease causal factors

Primary cause: persistent infection with oncogenic high-risk HPV (especially HPV16) leading to malignant transformation of oropharyngeal mucosa. (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3, wu2024deescalationstrategiesin pages 1-2)

Mechanistic causal factors (viral-host interactions): - Viral oncogenes E6 and E7 promote malignant transformation through canonical tumor suppressor interference (p53 and RB axis). Wu et al. explicitly summarize: “E6 was found to specifically degrade p53” and “E7 binds to the unphosphorylated region of retinoblastoma (Rb).” (wu2024deescalationstrategiesin pages 1-2)

Risk factors

  • HPV exposure (sexually transmitted; oropharyngeal exposure linked to sexual behavior). OPSCC tumors driven by HPV contrast with conventional carcinogen-driven OPSCC (alcohol/tobacco). (yan2024decipheringtheinterplay pages 1-2, krsek2024thenextchapter pages 1-2)
  • Tobacco/alcohol remain important external risk factors for HNSCC broadly, and for HPV-negative OPSCC in particular; HPV-negative OPSCC is “caused primarily by conventional carcinogens like alcohol or tobacco exposure.” (yan2024decipheringtheinterplay pages 1-2)

Protective factors

  • Prophylactic HPV vaccination is the primary prevention strategy; Ndon et al. state: “HPV vaccination is currently the main preventative approach for HPV-associated oropharyngeal cancer.” (Published 13 Aug 2023; https://doi.org/10.3390/cancers15164080) (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3)

Gene–environment / virus–environment interaction (evidence-supported components)

  • HPV-negative vs HPV-positive disease reflects different etiologic exposures (tobacco/alcohol vs HPV). (yan2024decipheringtheinterplay pages 1-2)
  • HPV integration biology (see Mechanisms) suggests a viral–host genome interaction that influences immune infiltration and outcomes. (tabatabaeian2024navigatingtherapeuticstrategies pages 1-2)

3. Phenotypes

Clinical presentation (limited by available evidence)

The retrieved texts emphasized epidemiology, diagnostics, immune biology, and treatment strategy rather than symptom frequencies. Nonetheless, several clinically relevant patterns were present:

  • Nodal disease prominence (clinical behavior): HPV+ OPSCC often presents with clinically significant cervical nodal disease despite favorable prognosis (not quantified in the evidence corpus here).
  • Treatment-related morbidity affecting quality of life: major toxicities motivating de-intensification include swallowing dysfunction and other head-and-neck functional sequelae. E3311 includes swallowing/QOL endpoints, and PATHOS explicitly centers swallowing function (MDADI). (NCT01898494 chunk 1, NCT02215265 chunk 1)

Quality of life impact (evidence-supported)

  • PATHOS’ stated main objective: “To assess whether swallowing function can be improved … by reducing the intensity of adjuvant treatment protocols.” (NCT02215265 chunk 1)

Suggested HPO terms (expert-curated; not directly asserted with frequencies in the retrieved evidence)

  • Dysphagia — HP:0002015
  • Odynophagia — HP:0033050
  • Cervical lymphadenopathy — HP:0000453
  • Weight loss — HP:0001824
  • Xerostomia (treatment-related, esp. radiotherapy) — HP:0000217
  • Dysarthria — HP:0001260

Note: Frequencies and onset distributions were not extractable from the current evidence set.

4. Genetic/Molecular Information

Viral molecular drivers

  • High-risk HPV, particularly HPV16, is the dominant subtype in OPSCC; Ndon et al. state: “an estimated 30% of oropharyngeal squamous cell carcinomas … are driven by HPV, with HPV16 being the most common subtype associated with malignancy.” (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3)
  • E6/E7 oncogene activity is central to oncogenic mechanism (p53/RB axis). (wu2024deescalationstrategiesin pages 1-2)

Viral integration status (clinically important subtype concept)

Tabatabaeian et al. describe three HPV genome states in tumors: “integrated … episomal … or a mixture,” and highlight outcome differences: “patients with HPV-positive head and neck cancers generally have a good prognosis except for a group of patients with fully integrated HPV who show worst clinical outcomes. Those patients present with lowered expression of viral genes and limited infiltration of cytotoxic T cells.” (Published online 20 Apr 2024; https://doi.org/10.1038/s41416-024-02655-1) (tabatabaeian2024navigatingtherapeuticstrategies pages 1-2)

Host genomic alterations

The current evidence set does not provide primary data on specific recurrent somatic driver frequencies (e.g., PIK3CA, TRAF3, CYLD) in HPV+ OPSCC. (Reference lists hint at these topics but without extractable numeric evidence.) (atique2024comprehensiveanalysisof pages 55-58, cleere2024hpvovertakessmoking pages 9-9)

Epigenetics

Not directly extractable from retrieved primary evidence; discussed as a general biomarker domain in diagnostic reviews. (krsek2024thenextchapter pages 1-2)

5. Mechanism / Pathophysiology

Causal chain (evidence-based backbone)

  1. Exposure and infection of oropharyngeal mucosa with high-risk HPV (often HPV16). (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3)
  2. Viral oncogene expression (E6/E7) disrupts tumor suppressor pathways: p53 degradation and RB-axis interference. (wu2024deescalationstrategiesin pages 1-2)
  3. Tumor evolution with distinct immune microenvironment, often immune-infiltrated (“immune hot” concept is widely discussed in this field; in the evidence here, the immune-rich TME is directly analyzed by single-cell methods). (yan2024decipheringtheinterplay pages 1-2)
  4. Clinical phenotype: HPV+ OPSCC tends to have more favorable prognosis overall, but with heterogeneity (e.g., integration status, discordant biomarker subsets). (craig2019recommendationsfordetermining pages 1-2, tabatabaeian2024navigatingtherapeuticstrategies pages 1-2)

Immune microenvironment (2024 single-cell evidence)

Yan et al. performed scRNA-seq on HPV+ and HPV− OPSCC (3 tumors each + normal tonsil), finding: - “HPV+ OPSCC tumor cells manifest an enhanced interferon response and elevated expression of the major histocompatibility complex II (MHC-II)” (yan2024decipheringtheinterplay pages 1-2) - They identify “a CXCL13+CD4+ T cell subset …” and report that interaction with HPV+ tumor cells “amplifies CXCL13 and IFNγ release … fostering a pro-inflammatory TME.” (yan2024decipheringtheinterplay pages 1-2) - They also note real-world clinical limitation: “the actual response rates of [immune checkpoint blockade] … remained relatively low (approximately 20%).” (yan2024decipheringtheinterplay pages 1-2)

Pathways / processes (ontology suggestions)

GO Biological Process (examples): - Interferon-gamma-mediated signaling pathway — GO:0060333 (supported conceptually by IFNγ/interferon response findings) (yan2024decipheringtheinterplay pages 1-2) - Antigen processing and presentation of peptide antigen via MHC class II — GO:0002495 (MHC-II elevation) (yan2024decipheringtheinterplay pages 1-2) - Regulation of T cell activation — GO:0050863 (CXCL13+ CD4+ interactions) (yan2024decipheringtheinterplay pages 1-2)

Cell Ontology (CL) suggestions: - CD4-positive, alpha-beta T cell — CL:0000624 (yan2024decipheringtheinterplay pages 1-2) - Cytotoxic T cell (CD8+ T cell) — CL:0000625 (integration-associated reduced cytotoxic T infiltration concept) (tabatabaeian2024navigatingtherapeuticstrategies pages 1-2)

GO Cellular Component suggestions: - MHC protein complex — GO:0042611 (yan2024decipheringtheinterplay pages 1-2)

6. Diagnostics

Current standard concepts (tissue-based)

  • p16 immunohistochemistry is widely used as a practical surrogate marker, but discordance exists (p16+ may not always indicate transcriptionally active HPV). Craig et al. emphasize TNM8’s use of p16 as surrogate and demonstrate prognostic misclassification when HPV is not transcriptionally active. (craig2019recommendationsfordetermining pages 1-2)

Quantitative performance evidence (2023)

Yang et al. compared Aptima HR-HPV E6/E7 mRNA testing on cytology specimens with p16 IHC on biopsies in 60 HNSCC patients (39 OPSCC): - “overall concordance rate … 95.0%” (yang2023aptimahrhpvtesting pages 1-2) - “sensitivity and negative predictive values … consistent at 100%” (Aptima and p16 IHC) (yang2023aptimahrhpvtesting pages 1-2) - “specificity and positive predictive values were 96.9% and 96.6% versus 93.8% and 93.3%, respectively.” (Aptima vs p16 IHC) (Published online 13 Dec 2022 in Acta Cytologica 2023; https://doi.org/10.1159/000527951) (yang2023aptimahrhpvtesting pages 1-2)

Clinical importance of p16/HPV discordance (2019, staging-relevant)

Craig et al. show that a p16+ but HPV− (transcriptionally inactive HPV) subgroup has significantly worse survival: - “Patients who tested p16+ but were HPV− (n = 20) had significantly reduced five-year survival (33%) compared to p16+ patients (77%) but not p16− patients (35%).” (craig2019recommendationsfordetermining pages 1-2) - They conclude these findings are relevant for de-escalation because p16-only staging can downstage biologically higher-risk patients. (craig2019recommendationsfordetermining pages 1-2)

Suggested diagnostic tests / biomarkers (evidence-based categories)

  • p16 IHC (screening surrogate) (yang2023aptimahrhpvtesting pages 1-2)
  • HPV E6/E7 mRNA assays (e.g., Aptima; RNA-based evidence of transcriptional activity) (yang2023aptimahrhpvtesting pages 1-2)
  • HPV DNA and genotyping (PCR-based in Yan et al. patient classification; HPV DNA detection used to confirm HPV status) (yan2024decipheringtheinterplay pages 1-2)

7. Treatment

Standard modalities (current practice)

Standard treatment remains multimodal (surgery and/or radiotherapy ± chemotherapy), and HPV+ disease’s better prognosis has motivated attempts to reduce treatment morbidity while maintaining control. (krsek2024thenextchapter pages 1-2, wu2024deescalationstrategiesin pages 1-2)

De-intensification / risk-adapted treatment (real-world implementation: ongoing trials)

ECOG-ACRIN E3311 (NCT01898494; Phase II; p16+ locally advanced, resectable OPC) - Official title: “Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer” (NCT01898494 chunk 1) - Key design: all patients undergo transoral surgery, then risk stratification: - Intermediate-risk randomized: 50 Gy/25 fx vs 60 Gy/30 fx IMRT (NCT01898494 chunk 1) - High-risk: 66 Gy/33 fx IMRT + weekly cisplatin (days 1, 8, 15, 22, 29, 36, 43) (NCT01898494 chunk 1) - Enrollment: 519; status ACTIVE_NOT_RECRUITING; results posted 28 Sep 2022 (registry metadata). (NCT01898494 chunk 1)

PATHOS (NCT02215265; Phase III; post-operative risk-stratified adjuvant therapy after transoral surgery) - Official title: “A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment … HPV-Positive Oropharyngeal Cancer” (NCT02215265 chunk 1) - Objective includes swallowing/QoL and non-inferiority for survival: “To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival …” (NCT02215265 chunk 1) - Radiation de-escalation arms: - Group B: PORT 60 Gy/30 fx vs 50 Gy/25 fx (NCT02215265 chunk 1) - Group C: POCRT 60 Gy/30 fx + cisplatin vs PORT 60 Gy/30 fx without chemotherapy (NCT02215265 chunk 1) - Target enrollment increased to 1269 (protocol amendment March 2024). (NCT02215265 chunk 1)

Immunotherapy considerations

Despite immune infiltration in HPV+ OPSCC, checkpoint blockade responses are heterogeneous and “approximately 20%” in the Yan et al. framing, motivating deeper TME stratification and biomarker development. (yan2024decipheringtheinterplay pages 1-2)

Suggested MAXO terms (ontology suggestions)

  • Radiotherapy — MAXO:0000027
  • Chemotherapy — MAXO:0000077
  • Surgical resection — MAXO:0000445
  • Immunotherapy — MAXO:0000127
  • Swallowing rehabilitation — MAXO:0000746

8. Outcome / Prognosis

Survival differences (HPV+ vs HPV−)

  • In an Irish single-center cohort (2012–2021), HPV+ OPSCC had higher short-term survival:
  • “2-year OS (83.9% vs. 54.9%; p < 0.001)” and “2-year DFS (73.5% vs. 45.6%; p < 0.001)” for HPV+ vs HPV−. (Cleere et al., 2024; https://doi.org/10.1007/s11845-024-03715-4) (cleere2024hpvovertakessmoking pages 1-2)

Prognostic pitfalls of surrogate testing (p16 discordance)

Craig et al. demonstrate clinically important survival divergence: - “p16+/HPV− … five-year survival (33%) compared to p16+ patients (77%)” and similar to p16− (35%). (craig2019recommendationsfordetermining pages 1-2) - Mortality risk under TNM8 downstaging: “mortality rate twice (HR 2.66 [95% CI: 1.37–5.15]) that of p16+/HPV+ patients …” (craig2019recommendationsfordetermining pages 1-2)

Molecularly informed prognosis (integration status)

Tabatabaeian et al. emphasize that fully integrated HPV correlates with “worst clinical outcomes” and limited cytotoxic T-cell infiltration, suggesting integration status is a candidate prognostic and predictive biomarker beyond HPV positivity alone. (tabatabaeian2024navigatingtherapeuticstrategies pages 1-2)

9. Inheritance and Population

Epidemiology and incidence trends (recent quantitative data)

United States (SEER 2010–2017 OPSCC; 2024 analysis) - HPV testing uptake increased from 21.95% (2010) to 51.37% (2014). - HPV positivity among tested OPSCC increased from 66.37% (2010) to 79.32% (2016). - Higher HPV positivity in tonsil and base of tongue vs posterior pharyngeal wall / soft palate. (Kim et al., 2024; https://doi.org/10.1186/s13027-024-00592-5) (kim2024aseerbasedanalysis pages 1-2)

Ireland (Dublin tertiary center, 2012–2021) - HPV+ proportion: 59.5% (175/294). - HPV-linked OPSCC proportion rose from 50.4% (2012–2016) to 65.4% (2017–2021) (p=0.011). (cleere2024hpvovertakessmoking pages 1-2)

Global estimates and regional variation (review synthesis, 2023) - Ndon et al.: “Across the globe, an estimated 30% of oropharyngeal squamous cell carcinomas … are driven by HPV …” (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3) - North America ASIR and attributable fraction (as summarized in the paper’s extracted text): “ASIR … 3.41 per 100,000 in males and 0.71 in females … ~63% [attributable fraction].” (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3)

Population demographics and disparities (limited by evidence)

Age/sex and policy disparities were discussed at a high level; detailed race/ethnicity-specific incidence or prevalence was not retrieved as primary evidence in this run.

10. Prevention

Primary prevention: HPV vaccination

Ndon et al. emphasize vaccination as primary prevention and highlight policy gaps: - “HPV vaccinations are the primary mode of prevention for HPV-associated OPSCC …” (ndon2023humanpapillomavirusassociatedoropharyngeal pages 10-12) - “As of 2022, 122 of 195 (63%) WHO member states had incorporated HPV vaccinations nationally; of these, 41 of 122 (34%) member states have introduced gender-neutral vaccine coverage.” (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3)

They also cite oral infection impact: “Studies have shown that HPV vaccinations have an efficacy of 88–93% against oral HPV infection …” (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3)

Real-world implementation gaps (2024 US example)

Adekanmbi et al. (Texas, 2006–2022 vaccination; 2016–2020 cancer IR) show wide geographic variation: - County-level 2021–2022 initiation ranges: 6.3%–69.1% (females) and 7.0%–77.6% (males) ages 9–17. - Up-to-date ranges: 1.6%–30.4% (females) and 2.1%–34.8% (males). - Counties with lower vaccination had higher HPV-related cancer incidence, raising equity concerns. (Published 5 Sep 2024; https://doi.org/10.1001/jamanetworkopen.2024.31807) (adekanmbi2024humanpapillomavirusvaccination pages 1-2)

11. Other Species / Natural Disease

Not addressed in the retrieved evidence corpus.

12. Model Organisms / Experimental Systems

The retrieved evidence set did not include explicit descriptions of animal models or organoid systems for HPV+ OPSCC. This section is therefore not evidence-complete in the current run.

Evidence Synthesis Artifact

The following evidence table consolidates the most directly supported quantitative statements and implementation-relevant facts extracted in this run.

Domain Key findings Key source Identifier
Epidemiology In the US SEER 2010-2017 cohort of 13,081 OPSCC cases, HPV testing increased from 21.95% (2010) to 51.37% (2014), and HPV positivity among tested OPSCC cases increased from 66.37% (2010) to 79.32% (2016); positivity was higher in tonsil/base of tongue than soft palate/posterior pharyngeal wall (kim2024aseerbasedanalysis pages 1-2) Kim et al., 2024, Infectious Agents and Cancer DOI: 10.1186/s13027-024-00592-5
Epidemiology In a Dublin tertiary-center series (2012-2021, n=294), 59.5% (175/294) of OPSCC cases were HPV-positive; the proportion of HPV-linked OPSCC rose from 50.4% in 2012-2016 to 65.4% in 2017-2021 (p=0.011) (cleere2024hpvovertakessmoking pages 1-2) Cleere et al., 2024, Irish Journal of Medical Science DOI: 10.1007/s11845-024-03715-4
Epidemiology Globally, ~30% of OPSCC is HPV-driven; incidence is highest in North America, Europe, and Oceania. North America ASIR was 3.41/100,000 in males and 0.71/100,000 in females, with an attributable fraction of ~63% (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3) Ndon et al., 2023, Cancers DOI: 10.3390/cancers15164080
Etiology/Mechanism HPV16 is the dominant high-risk subtype; HPV genomes in tumors can be integrated, episomal, or mixed. Fully integrated HPV is associated with worse outcomes, lower viral gene expression, and reduced cytotoxic T-cell infiltration (tabatabaeian2024navigatingtherapeuticstrategies pages 1-2) Tabatabaeian et al., 2024, British Journal of Cancer DOI: 10.1038/s41416-024-02655-1
Etiology/Mechanism Single-cell RNA-seq of 3 HPV+ and 3 HPV- OPSCC tumors plus normal tonsil showed HPV+ tumor cells have enhanced interferon response, elevated MHC-II expression, and crosstalk with CXCL13+CD4+ T cells; ICB response rates in HPV+ OPSCC remain only ~20% despite immune-rich TME (yan2024decipheringtheinterplay pages 1-2) Yan et al., 2024, Cancer Immunology, Immunotherapy DOI: 10.1007/s00262-024-03789-0
Diagnostics In 60 HNSCC cases (39 OPSCC), Aptima E6/E7 mRNA testing and p16 IHC were 95.0% concordant. Sensitivity and NPV were 100% for both; specificity/PPV were 96.9%/96.6% for Aptima versus 93.8%/93.3% for p16 IHC. HPV prevalence was 61.5% (24/39) in OPSCC (yang2023aptimahrhpvtesting pages 1-2) Yang et al., 2023, Acta Cytologica DOI: 10.1159/000527951
Diagnostics A UK OPSCC cohort showed up to ~20% of p16+ OPSCC may lack transcriptionally active HPV; p16+/HPV- patients had markedly inferior outcomes, supporting two-tier testing with HPV-specific assays (RNA/DNA ISH) rather than p16 alone for staging/de-escalation decisions (craig2019recommendationsfordetermining pages 1-2) Craig et al., 2019, British Journal of Cancer DOI: 10.1038/s41416-019-0414-9
Prognosis In the Dublin series, HPV+ OPSCC had better 2-year overall survival (83.9% vs 54.9%) and disease-free survival (73.5% vs 45.6%) than HPV- disease (both p<0.001) (cleere2024hpvovertakessmoking pages 1-2) Cleere et al., 2024, Irish Journal of Medical Science DOI: 10.1007/s11845-024-03715-4
Prognosis In p16+/HPV- OPSCC (n=20), 5-year survival was 33% versus 77% in p16+/HPV+ disease; 95% were downstaged by TNM8 despite mortality about twice that of p16+/HPV+ patients (HR 2.66, 95% CI 1.37-5.15) (craig2019recommendationsfordetermining pages 1-2) Craig et al., 2019, British Journal of Cancer DOI: 10.1038/s41416-019-0414-9
Treatment/Trials ECOG-ACRIN E3311 is a phase II randomized trial in resectable p16+ locally advanced OPC: all patients undergo transoral surgery, then risk-adapted therapy. Intermediate-risk patients are randomized to 50 Gy/25 fractions versus 60 Gy/30 fractions IMRT; high-risk patients receive 66 Gy plus cisplatin. Enrollment: 519 (NCT01898494 chunk 1) ECOG-ACRIN E3311 registry entry NCT01898494
Treatment/Trials PATHOS is a phase III risk-stratified post-transoral surgery trial in HPV+ OPSCC. Intermediate-risk group: PORT 60 Gy/30 fractions vs 50 Gy/25 fractions; high-risk group: POCRT 60 Gy with cisplatin vs PORT 60 Gy alone. Co-primary endpoints include MDADI swallowing score and overall survival. Target enrollment increased to 1269 (NCT02215265 chunk 1) PATHOS registry entry NCT02215265
Prevention/Policy HPV vaccination is the main preventive strategy; studies cited in the review report 88-93% efficacy against oral HPV infection when given prior to sexual debut (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3) Ndon et al., 2023, Cancers DOI: 10.3390/cancers15164080
Prevention/Policy As of 2022, 122/195 (63%) WHO member states had national HPV vaccination programs, but only 41/122 (34%) had gender-neutral vaccination coverage (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3, ndon2023humanpapillomavirusassociatedoropharyngeal pages 10-12) Ndon et al., 2023, Cancers DOI: 10.3390/cancers15164080
Prevention/Policy In Texas, county-level HPV vaccine initiation in 2021-2022 ranged from 6.3%-69.1% in females and 7.0%-77.6% in males aged 9-17; up-to-date coverage ranged from 1.6%-30.4% in females and 2.1%-34.8% in males, underscoring prevention gaps (adekanmbi2024humanpapillomavirusvaccination pages 1-2) Adekanmbi et al., 2024, JAMA Network Open DOI: 10.1001/jamanetworkopen.2024.31807

Table: This table compiles concise, evidence-backed facts on HPV-positive head and neck squamous cell carcinoma, with emphasis on HPV-positive OPSCC. It highlights the most actionable findings from the gathered sources across epidemiology, mechanism, diagnostics, prognosis, trials, and prevention.

Expert analysis and key takeaways (evidence-grounded)

  1. HPV+ OPSCC is expanding as a public health burden, with increasing HPV positivity proportions in US SEER OPSCC and rising HPV-linked fractions in institutional cohorts. (kim2024aseerbasedanalysis pages 1-2, cleere2024hpvovertakessmoking pages 1-2)
  2. Biological heterogeneity matters: HPV integration status may identify a poorer-prognosis subgroup with reduced cytotoxic T infiltration, suggesting that “HPV-positive” is not a sufficient classifier for therapeutic decision-making. (tabatabaeian2024navigatingtherapeuticstrategies pages 1-2)
  3. Testing strategy has direct clinical consequences: p16-only classification can mis-stage biologically distinct tumors; p16+/HPV− tumors have survival closer to HPV-negative disease, supporting two-tier HPV testing. (craig2019recommendationsfordetermining pages 1-2, yang2023aptimahrhpvtesting pages 1-2)
  4. Immune biology is complex: scRNA-seq supports enhanced interferon/MHC-II programs in HPV+ tumor cells and CXCL13+CD4+ interactions, but checkpoint inhibitor response rates remain ~20%, reinforcing the need for better predictive biomarkers. (yan2024decipheringtheinterplay pages 1-2)
  5. De-intensification is being operationalized through risk-stratified surgical pathways (E3311, PATHOS), with co-primary functional outcomes (swallowing) embedded—reflecting a mature shift from purely survival endpoints toward survivorship optimization. (NCT01898494 chunk 1, NCT02215265 chunk 1)

Limitations of this report

Several template elements (ontology IDs, detailed phenotype frequencies, specific host somatic driver gene frequencies, animal models) were not retrievable from the current tool-acquired evidence corpus and are therefore explicitly not fully populated. Where ontology terms were suggested, they are presented as candidate mappings rather than evidence-derived annotations.

References

  1. (yan2024decipheringtheinterplay pages 1-2): Shida Yan, Xing Zhang, Qiaohong Lin, Mingyuan Du, Yiqi Li, Shuai He, Jingtao Chen, Xiyuan Li, Jinxin Bei, Shuwei Chen, and Ming Song. Deciphering the interplay of hpv infection, mhc-ii expression, and cxcl13+ cd4+ t cell activation in oropharyngeal cancer: implications for immunotherapy. Cancer Immunology, Immunotherapy : CII, Aug 2024. URL: https://doi.org/10.1007/s00262-024-03789-0, doi:10.1007/s00262-024-03789-0. This article has 11 citations.

  2. (ndon2023humanpapillomavirusassociatedoropharyngeal pages 1-3): Sifon Ndon, Amritpal Singh, Patrick K. Ha, Joyce Aswani, Jason Ying-Kuen Chan, and Mary Jue Xu. Human papillomavirus-associated oropharyngeal cancer: global epidemiology and public policy implications. Cancers, 15:4080, Aug 2023. URL: https://doi.org/10.3390/cancers15164080, doi:10.3390/cancers15164080. This article has 58 citations.

  3. (craig2019recommendationsfordetermining pages 1-2): Stephanie G. Craig, Lesley A. Anderson, Andrew G. Schache, Michael Moran, Laura Graham, Keith Currie, Keith Rooney, Max Robinson, Navdeep S. Upile, Rachel Brooker, Mina Mesri, Victoria Bingham, Stephen McQuaid, Terry Jones, Dennis J. McCance, Manuel Salto-Tellez, Simon S. McDade, and Jacqueline A. James. Recommendations for determining hpv status in patients with oropharyngeal cancers under tnm8 guidelines: a two-tier approach. British Journal of Cancer, 120:827-833, Mar 2019. URL: https://doi.org/10.1038/s41416-019-0414-9, doi:10.1038/s41416-019-0414-9. This article has 121 citations and is from a domain leading peer-reviewed journal.

  4. (kim2024aseerbasedanalysis pages 1-2): Su Il Kim, Jung Woo Lee, Young-Gyu Eun, and Young Chan Lee. A seer-based analysis of trends in hpv-associated oropharyngeal squamous cell carcinoma. Infectious Agents and Cancer, Jun 2024. URL: https://doi.org/10.1186/s13027-024-00592-5, doi:10.1186/s13027-024-00592-5. This article has 12 citations and is from a peer-reviewed journal.

  5. (cleere2024hpvovertakessmoking pages 1-2): Eoin F. Cleere, Josh Murphy, Thomas J. Crotty, Justin M. Hintze, Conrad V. I. Timon, John Kinsella, Conall W. R. Fitzgerald, and Paul Lennon. Hpv overtakes smoking as the leading cause of oropharyngeal cancer in ireland: experience of a head and neck surgery tertiary referral centre. Irish Journal of Medical Science, 193:2161-2169, May 2024. URL: https://doi.org/10.1007/s11845-024-03715-4, doi:10.1007/s11845-024-03715-4. This article has 5 citations and is from a peer-reviewed journal.

  6. (NCT01898494 chunk 1): Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer. ECOG-ACRIN Cancer Research Group. 2014. ClinicalTrials.gov Identifier: NCT01898494

  7. (NCT02215265 chunk 1): Lisette Nixon. Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS). Lisette Nixon. 2015. ClinicalTrials.gov Identifier: NCT02215265

  8. (wu2024deescalationstrategiesin pages 1-2): Clinton Wu, Paulina Kuzmin, and Ricklie Julian. De-escalation strategies in hpv-associated oropharynx cancer: a historical perspective with future direction. Cancers, 16:2733, Aug 2024. URL: https://doi.org/10.3390/cancers16152733, doi:10.3390/cancers16152733. This article has 10 citations.

  9. (krsek2024thenextchapter pages 1-2): Antea Krsek, Lara Baticic, Tamara Braut, and Vlatka Sotosek. The next chapter in cancer diagnostics: advances in hpv-positive head and neck cancer. Biomolecules, 14:925, Jul 2024. URL: https://doi.org/10.3390/biom14080925, doi:10.3390/biom14080925. This article has 12 citations.

  10. (tabatabaeian2024navigatingtherapeuticstrategies pages 1-2): Hossein Tabatabaeian, Yuchen Bai, Ruihong Huang, Akhilanand Chaurasia, and Charbel Darido. Navigating therapeutic strategies: hpv classification in head and neck cancer. British Journal of Cancer, 131:220-230, Apr 2024. URL: https://doi.org/10.1038/s41416-024-02655-1, doi:10.1038/s41416-024-02655-1. This article has 36 citations and is from a domain leading peer-reviewed journal.

  11. (atique2024comprehensiveanalysisof pages 55-58): M Atique. Comprehensive analysis of genetic mutations in hpv-positive and hpv-negative oropharyngeal squamous cell carcinoma: a literature review. Unknown journal, 2024.

  12. (cleere2024hpvovertakessmoking pages 9-9): Eoin F. Cleere, Josh Murphy, Thomas J. Crotty, Justin M. Hintze, Conrad V. I. Timon, John Kinsella, Conall W. R. Fitzgerald, and Paul Lennon. Hpv overtakes smoking as the leading cause of oropharyngeal cancer in ireland: experience of a head and neck surgery tertiary referral centre. Irish Journal of Medical Science, 193:2161-2169, May 2024. URL: https://doi.org/10.1007/s11845-024-03715-4, doi:10.1007/s11845-024-03715-4. This article has 5 citations and is from a peer-reviewed journal.

  13. (yang2023aptimahrhpvtesting pages 1-2): Xin Yang, Chunfang Hu, Huan Zhao, Zhi-hui Zhang, LinLin Zhao, Jing Yu, Xiaoguang Ni, and Huiqin Guo. Aptima hr-hpv testing of cytology specimens is an effective supplement for p16 staining to improve diagnostic accuracy for hpv-related oropharyngeal squamous cell carcinoma. Acta Cytologica, 67:321-332, Dec 2023. URL: https://doi.org/10.1159/000527951, doi:10.1159/000527951. This article has 7 citations and is from a peer-reviewed journal.

  14. (ndon2023humanpapillomavirusassociatedoropharyngeal pages 10-12): Sifon Ndon, Amritpal Singh, Patrick K. Ha, Joyce Aswani, Jason Ying-Kuen Chan, and Mary Jue Xu. Human papillomavirus-associated oropharyngeal cancer: global epidemiology and public policy implications. Cancers, 15:4080, Aug 2023. URL: https://doi.org/10.3390/cancers15164080, doi:10.3390/cancers15164080. This article has 58 citations.

  15. (adekanmbi2024humanpapillomavirusvaccination pages 1-2): Victor Adekanmbi, Itunu Sokale, Fangjian Guo, Jessica Ngo, Thao N. Hoang, Christine D. Hsu, Abiodun Oluyomi, and Abbey B. Berenson. Human papillomavirus vaccination and human papillomavirus–related cancer rates. JAMA Network Open, 7:e2431807, Sep 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.31807, doi:10.1001/jamanetworkopen.2024.31807. This article has 13 citations and is from a peer-reviewed journal.